NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Neoadjuvant publications

Evidence / Neoadjuvant

5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

ย  PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Michael Rotkis, Angela Mislowsky, Carrie Dul, Charles Nash, BichlienNguyen, Mary Murray, Paul Richards, Mark Gittleman, Stephanie Akbari, ShiyuWang, Erin B Yoder, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group Background: MammaPrint Read More

ASCO 2020: Chemokine Signature

PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Charles Cox, Pat Whitworth, Sahra Uygun, Heather M. Kling, Erin B. Yoder, and William Audeh SUMMARY: Studies demonstrating the presence of immunoregulatory gene activation1 and tumor- infiltrating lymphocytes in the breast tumor microenvironment suggest the importance of an effective anti-tumor Read More

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, Read More

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2โˆ’) breast cancers are classified clinically as Luminal-type. We showed previously that molecular Read More

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van โ€˜t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrintยฎ Read More